Cambridge, Massachusetts - On December 11, 2024, Full Circles Therapeutics " Full Circles " , a company in which Via Biotech participated in the angel round of investment, published a breakthrough study " Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration " in the top journal Nature Biotechnology . This study introduces a new non-viral circular single-stranded DNA technology cssDNA, which can achieve efficient large-fragment gene access in a variety of cell types and can carry gene sequences up to 20Kb in length.
I-Mab and Jichuan Pharmaceuticals jointly announced that the sri lanka telegram data application for the marketing approval of Etan long-acting growth hormone has been accepted
Hangzhou, China - On December 9, 2024, I-Mab, a full-industry chain biotechnology company focused on the development, production and co-commercialization of innovative biological drugs in the fields of autoimmune diseases and tumors, co-invested by Viva Biotech, and Jichuan Pharmaceutical Group Co., Ltd. hereinafter referred to as " Jichuan Pharmaceutical " jointly announced that the biologics marketing application BLA of Etan long-acting recombinant human growth hormone injection hereinafter referred to as " Etan long-acting growth hormone " for the treatment of childhood growth hormone deficiency PGHD has been accepted by the China National Medical Products Administration NMPA. As the first and only fusion protein long-acting growth hormone in the domestic application stage and on the market, this innovative therapy is expected to provide a safe, effective and more convenient treatment option for children with growth hormone deficiency.